The smarter E Europe: Smart Integration Saves Cash and Stabilizes Grids
‘Accelerating Integrated Energy Solutions’ - this is the motto of The smarter E Europe 2025, which will take place this year from 7 to 9 May at Messe München.Smart integration is crucial in the evolving energy and mobility sectors. Energy management systems (EMS) for prosumers and businesses have shifted from a nice-to-have to a must-have, making them a key topic at this year’s event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212149082/en/
At The smarter E Europe 2025, visitors will find everything for the smart interaction of PV, storage, e-mobility and energy management. (Photo: Solar Promotion GmbH)
GridX, a smart energy company, estimates that the European Home Energy Management System (HEMS) market will expand 11-fold by 2030 across Denmark, Germany, the UK, Italy, the Netherlands, Austria, Sweden, and Spain. This rapid growth reflects increasing demand and evolving regulations.
Regulatory and market requirements
Regulations such as Section 14a of Germany’s Energy Industry Act (EnWG) allow grid operators to control the power output of heat pumps, EV chargers, and battery storage systems. A robust EMS can optimize energy use, reducing reliance on the grid without compromising user comfort.
The challenge of interoperability
Interoperability remains a challenge, with ongoing discussions about standardization. Manufacturer-independent solutions allow greater flexibility for customers. At The smarter E Europe, top industry leaders will address interoperability concerns, emphasizing open standards. In 2018, the OpenEMS Association took a leading role in supporting efforts to create open and manufacturer-independent standards for energy management systems. OpenEMS is not a communication protocol, such as EEBus, but a software platform. The Association counts universities and research institutes, grid operators and industry associations as well as energy management companies among its members.
Focus event hosted by pv magazine and The smarter E Forum
Home energy management is also going to be discussed at the focus event hosted by pv magazine on the second exhibition day, May 8, 2025. Two interactive sessions will shed light on key aspects of quality photovoltaics and storage projects in the small and utility-scale sectors. pv magazine invites interested visitors to ICM – International Congress Center Messe München, room 13, from 1:00pm–5:00pm. It will be held in German. A separate, English-speaking session aimed at an international expert audience will focus on optimizing large-scale storage systems and the quality assurance of planning, design and marketing. Click here to register for the event.
The smarter E Forum will be organizing a dedicated session for prosumer home energy management systems. On Friday, May 9, the key role of HEMS for modern energy management and grid stability will be discussed starting from 1:30pm.
Munich becomes the center of the energy world
In May, at Messe München, innovation will meet practice, and visions will meet concrete solutions. The smarter E Europe shows how the sectors electricity, heat and transportation can be intelligently connected to create a decentralized, digitalized and flexible energy world. From May 7–9, 2025, Messe München is fully booked – the organizers expect more than 3,000 exhibitors and over 110,000 visitors at the exhibition ground covering 206,000 square meters across 19 exhibition halls and the Outdoor Area.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212149082/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom